Niki BioSolutions, Inc. (NIKI) - Total Assets
Based on the latest financial reports, Niki BioSolutions, Inc. (NIKI) holds total assets worth $18.69 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See today's stock price for Niki BioSolutions, Inc. for real-time trading data and today's change.
Niki BioSolutions, Inc. - Total Assets Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see cash flow conversion of Niki BioSolutions, Inc. for how efficiently the company converts equity into cash flow.
Niki BioSolutions, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Niki BioSolutions, Inc.'s total assets of $18.69 Million consist of 19.2% current assets and 80.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NIKI working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Niki BioSolutions, Inc.'s current assets represent 19.2% of total assets in 2025, a decrease from 64.3% in 2017.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 51.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Niki BioSolutions, Inc. Competitors by Total Assets
Key competitors of Niki BioSolutions, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
Niki BioSolutions, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.78 | 0.22 | 1.57 |
| Quick Ratio | 0.78 | 0.22 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.00 Million | $-3.38 Million | $9.59 Million |
Niki BioSolutions, Inc. - Advanced Valuation Insights
This section examines the relationship between Niki BioSolutions, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.32 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 15.9% |
| Total Assets | $18.69 Million |
| Market Capitalization | $5.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Niki BioSolutions, Inc.'s assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Niki BioSolutions, Inc.'s assets grew by 15.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Niki BioSolutions, Inc. (2017–2025)
The table below shows the annual total assets of Niki BioSolutions, Inc. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.69 Million | +15.88% |
| 2024-12-31 | $16.13 Million | -21.85% |
| 2023-12-31 | $20.64 Million | -1.09% |
| 2022-12-31 | $20.87 Million | -4.75% |
| 2021-12-31 | $21.91 Million | -50.47% |
| 2020-12-31 | $44.23 Million | +84.65% |
| 2019-12-31 | $23.95 Million | -46.86% |
| 2018-12-31 | $45.07 Million | +42.82% |
| 2017-12-31 | $31.56 Million | -- |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more